關於癌症疫苗臨床前研究的業務進展更新 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：0775） 整體而言，所發表之研究均呈現一致主題：通過理性設計的癌症疫苗，於多個腫瘤靶點及疫苗構建 體之臨床前模型中，均展現強勁免疫原性及顯著的抗腫瘤活性。在發表中展示之該等數據充分印證 順譜醫藥科技從抗原篩選轉化至功能性免疫反應及腫瘤控制上之優勢。在此基礎上，順譜醫藥科技 正加快推進最具潛力之研發項目的新藥臨床試驗申請（IND）支持性研究，並期望透過策略性合作與 全球協作，加快將選定候選疫苗推進至早期臨床開發階段。 務請注意，該研究目前僅處於臨床前階段，本公司尚未開始就該等疫苗進行臨床試驗，故目前概不能 保證相關成果。因此，本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 長江生命科技集團有限公司 公司秘書 楊逸芝 香港，二零二六年三月三十一日 於本公告日期，本公司執行董事為李澤鉅先生（主席）、甘慶林 ...

Core Viewpoint - The transaction involves the sale of 100% equity interest in ABCJ, LLC, a subsidiary of Changjiang Life Sciences Technology, to TransCode Therapeutics, Inc. for a total consideration of $125 million, with additional milestone payments potentially reaching $95 million [1][2]. Group 1: Transaction Details - The seller, through its indirect wholly-owned subsidiary DEFJ, LLC, will sell 100% of the issued equity of the target company for $125 million, payable through the issuance of shares by the buyer [1]. - The buyer will also pay milestone payments up to $95 million upon achieving certain milestones [1]. - An investment agreement will see the seller purchase preferred shares from the buyer for approximately $25 million [1]. Group 2: Target Company Overview - The target company, ABCJ, LLC, owns 100% of Polynoma, which focuses on the research, production, and commercialization of treatments for melanoma [2]. - Polynoma's flagship candidate, seviprotimut-L, is a proprietary multi-valent melanoma cancer vaccine [2]. - Post-transaction, the target company will no longer be a subsidiary of the seller, and its financial performance will not be consolidated into the seller's accounts [2]. Group 3: Strategic Implications - The merger is expected to create synergies between Polynoma and the buyer's product line, which addresses metastatic cancer, a significant unmet need in oncology [2]. - The buyer's product portfolio includes TTX-MC138, currently in Phase I/II clinical trials, and other preclinical candidates [2]. - Being a Nasdaq-listed entity, the buyer will enhance market exposure for seviprotimut-L and improve fundraising capabilities [3].

Core Viewpoint - The biotechnology sector is characterized by high returns and high risks, with successful products potentially surpassing the value of many listed infrastructure and real estate companies [1] Group 1: Company Strategy and Research - The company is currently engaged in multiple cancer vaccine research projects, including the TROP2 cancer vaccine, which has shown significant tumor growth inhibition in preclinical studies [1] - The TROP2 protein is overexpressed in various cancers, including triple-negative breast cancer, lung cancer, and colorectal cancer, with the company's vaccine demonstrating 100% tumor growth inhibition in mouse models [1] - The company estimates that it will take approximately 24-30 months to initiate Phase I/II clinical trials for the TROP2 vaccine [1] Group 2: Asset Management and Financial Strategy - The company considers its health products and agriculture-related businesses as important, generating stable cash flow to support research and development [1] - The company will continue to evaluate strategic options to enhance shareholder value and optimize its business structure, with any significant developments to be disclosed to the market [1] - There are currently no announcements regarding the potential spin-off of the biopharmaceutical division for a Hong Kong listing, and the company is assessing strategic opportunities to improve shareholder value [2] - The company has not announced any plans for fundraising through share placements or convertible bonds to support research and development [2]

Group 1 - Jiangsu Life Science Technology (00775.HK) recently announced promising early results from preclinical laboratory tests of its novel cancer vaccine targeting trophoblast cell surface antigen 2 (TROP2) [1] - The TROP2 vaccine has shown significant tumor growth inhibition in preclinical studies, with four out of five studies demonstrating 100% tumor growth suppression and one study showing approximately 80% suppression in over 170 mice [1] - The TROP2 vaccine is expected to become the first curative therapy for high-incidence cancers in Asia, addressing urgent clinical needs and potentially covering multiple cancer types such as lung and pancreatic cancer [1] Group 2 - The company has multiple clinical-stage medical research projects and its R&D product line is considered severely undervalued, with potential for value release and substantial performance contributions [2] - The company reported a nearly 60% year-on-year increase in clinical trial and laboratory expenses, reaching HKD 161 million in 2024, indicating a strong commitment to R&D [2] - The company is exploring various strategic options, including strategic partnerships, joint ventures, business spin-offs, and mergers, to maximize shareholder value and enhance its capital acquisition channels [2]

Group 1 - The company, Changjiang Life Science Technology, has announced promising early results from preclinical laboratory tests of a novel cancer vaccine targeting TROP2, a cell surface glycoprotein overexpressed in various cancers such as breast, lung, pancreatic, and colorectal cancers [1] - TROP2 plays a critical role in cell proliferation, metastasis, and invasion, making it a potential therapeutic target in oncology due to its high expression in cancer cells and minimal presence in normal tissues [1] - The TROP2 cancer vaccine candidate utilizes innovative circular RNA (circRNA) and fusion protein constructs, demonstrating significant tumor growth inhibition in preclinical studies involving over 170 mice, with complete tumor growth suppression observed in all breast cancer studies [1] Group 2 - The incidence of breast cancer, particularly triple-negative breast cancer (TNBC), is rising sharply in Asia, affecting many young women, with higher rates and severity compared to Western countries [2] - The company believes that the TROP2 cancer vaccine shows unprecedented anti-cancer efficacy based on mouse studies and aims to advance it to clinical research stages to provide new treatment options for patients [2] - The company has filed patent applications for the circRNA and fusion protein TROP2 cancer vaccine with the Hong Kong Intellectual Property Department and a provisional patent application with the U.S. Patent and Trademark Office [2] Group 3 - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on April 11, 2025 [3]